The acquisition of the US oncology-focused firm will immediately build the commercial presence of the affiliate of the major South Korean conglomerate in oncology through Fotivda, while bringing LG Chem a step closer to its ambitions of becoming a major global pharma operation.
LG Chem, Ltd. has entered into a definitive agreement to acquire the US-based commercial stage biopharma company AVEO Pharmaceuticals, Inc. in an all-cash deal worth $566m, marking the first time for a Korean pharma firm to buy a US oncology-focused operation with an FDA-approved new drug.
“The latest acquisition decision marks the most important milestone in the 40-year history of the biopharma business of the diversified...
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400)
